RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REGENXBIO Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$7.15+0.23 (+3.25%)
Close on Oct 19, 2026
- Market cap
- $379.06M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
64.2%
42M of 66M shares
Institutional holders
165
25 new, 35 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
2 buys · 5 sales
Net bought $9.57K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Redmile Group, LLC | 5,062,477 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| BlackRock, Inc. | 3,678,738 | 7.30% | 13G (passive) amendment | Mar 31, 2025 |
| JPMorgan Chase & Co. | 3,560,915 | 5.30% | 13G (passive) | Sep 30, 2026 |
| State Street Corporation | 2,731,553 | 5.30% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RGNX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,397,440 | 9.69% | $76.64M | +614,632 | 0.00% |
| Redmile Group, LLC | 4,368,804 | 6.62% | $52.34M | – | 3.51% |
| State Street Corp | 2,971,173 | 4.50% | $35.59M | +239,688 | 0.00% |
| JPMorgan Chase & Co | 2,214,169 | 3.35% | $26.19M | −1,269,631 | 0.00% |
| Vanguard Capital Management LLC | 2,107,557 | 3.19% | $25.25M | +100,411 | 0.00% |
| Morgan Stanley | 1,953,237 | 2.96% | $23.40M | −112,920 | 0.00% |
| Goldman Sachs Group Inc | 1,421,453 | 2.15% | $17.03M | −418,010 | 0.00% |
| Aqr Capital Management LLC | 1,378,358 | 2.09% | $16.51M | +326,646 | 0.01% |
| Vanguard Portfolio Management LLC | 1,355,554 | 2.05% | $16.24M | +336,653 | 0.00% |
| Marshall Wace, Llp | 1,284,950 | 1.95% | $15.39M | New | 0.01% |
| Geode Capital Management, LLC | 1,241,296 | 1.88% | $14.87M | +103,798 | 0.00% |
| Integral Health Asset Management, LLC | 800,000 | 1.21% | $9.58M | −700,000 | 0.38% |
| Nuveen, LLC | 740,026 | 1.12% | $8.87M | +158,010 | 0.00% |
| Dimensional Fund Advisors LP | 731,586 | 1.11% | $8.76M | −278,795 | 0.00% |
| D. E. Shaw & Co., Inc. | 712,814 | 1.08% | $8.54M | +426,813 | 0.00% |
| Two Sigma Investments, LP | 669,808 | 1.01% | $8.02M | +114,916 | 0.01% |
| Citadel Advisors LLC | 669,023 | 1.01% | $8.01M | New | 0.00% |
| Stifel Financial Corp | 560,727 | 0.85% | $6.72M | +167,958 | 0.01% |
| Bank Of America Corp /De/ | 518,545 | 0.79% | $6.21M | +193,685 | 0.00% |
| 22NW, LP | 492,759 | 0.75% | $5.90M | – | 5.64% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 165 | 42M | 64.2% | 25 / 62 | 52 / 35 | 7M | 8M |
| Q1 2026 | 178 | 43M | 64.6% | 33 / 60 | 59 / 26 | 8M | 3M |
| Q4 2025 | 174 | 41M | 62.4% | 24 / 63 | 60 / 14 | 4M | 8M |
| Q3 2025 | 166 | 45M | 68.8% | 23 / 64 | 52 / 15 | 8M | 5M |
| Q2 2025 | 159 | 42M | 63.7% | 25 / 60 | 51 / 28 | 7M | 6M |
| Q1 2025 | 164 | 42M | 63.1% | 34 / 51 | 53 / 44 | 6M | 6M |
| Q4 2024 | 177 | 42M | 63.8% | 39 / 57 | 51 / 44 | 7M | 11M |
| Q3 2024 | 186 | 46M | 69.9% | 31 / 65 | 50 / 25 | 13M | 5M |
| Q2 2024 | 181 | 47M | 70.8% | 25 / 74 | 48 / 30 | 5M | 7M |
| Q1 2024 | 188 | 49M | 74.2% | 40 / 61 | 52 / 23 | 8M | 3M |
| Q4 2023 | 171 | 44M | 66.5% | 32 / 47 | 61 / 20 | 11M | 4M |
| Q3 2023 | 159 | 37M | 56.3% | 17 / 62 | 52 / 25 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RGNX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,958,976 | 2.97% | $23.47M | 0.22% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,496,139 | 2.27% | $17.92M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,270,455 | 1.92% | $15.22M | 0.02% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 855,170 | 1.30% | $8.29M | 0.20% | Jul 31, 2026 |
| JPMorgan Small Cap Growth Fund | 629,843 | 0.95% | $7.55M | 0.29% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 564,476 | 0.86% | $6.76M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 527,935 | 0.80% | $5.12M | 0.02% | Jul 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 467,248 | 0.71% | $5.60M | 0.18% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 378,118 | 0.57% | $4.53M | 0.03% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 339,957 | 0.51% | $2.38M | 0.05% | May 29, 2026 |
| iShares Biotechnology ETF | 336,179 | 0.51% | $4.03M | 0.04% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 322,770 | 0.49% | $3.87M | 0.07% | Jun 30, 2026 |
| Vanguard Market Neutral Fund | 281,985 | 0.43% | $3.38M | 0.57% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 246,936 | 0.37% | $1.73M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 242,468 | 0.37% | $1.70M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Curran Simpson | Chief Executive Officer, Director | 338,053 | 0.51% | Jul 6, 2026 |
| Craig Malzahn | Chief Technology Officer | 81,960 | 0.12% | Sep 3, 2026 |
| Mitchell Chan | Chief Financial Officer | 122,815 | 0.19% | Sep 3, 2026 |
| Steve Pakola | Chief Medical Officer | 205,541 | 0.31% | Aug 4, 2026 |
| Patrick J. Christmas | Chief Strategy & Legal Officer | 205,968 | 0.31% | Aug 4, 2026 |
| Olivier Danos | Chief Scientific Officer | 226,348 | 0.34% | Apr 4, 2025 |
| Gregory Austin Ciongoli | Director | 118,035 | 0.18% | Aug 27, 2026 |
| Daniel Tasse | Director | 28,861 | 0.04% | Jun 2, 2026 |
| George V. Migausky | Director | 28,861 | 0.04% | Jun 2, 2026 |
| Jean Bennett | Director | 28,861 | 0.04% | Jun 2, 2026 |
| Jennifer Zachary | Director | 31,871 | 0.05% | Jun 2, 2026 |
| Argeris N. Karabelas | Director | 28,861 | 0.04% | Jun 2, 2026 |
| David C. Stump | Director | 28,861 | 0.04% | Jun 2, 2026 |
| Kenneth T. Mills | Director | 495,925 | 0.75% | Jun 2, 2026 |
| Allan M. Fox | Director | 2,911,327 | 4.41% | Jun 2, 2026 |
| Alexandra Glucksmann | Director | 28,861 | 0.04% | Jun 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mitchell Chan Chief Financial Officer | Sep 1, 2026 | Tax withholding | −4,902 | $9.32 | $45.69K | 122,815 |
| Craig Malzahn Chief Technology Officer | Sep 1, 2026 | Tax withholding | −234 | $9.32 | $2.18K | 81,960 |
| Gregory Austin Ciongoli Director | Aug 27, 2026 | Buy | +53,407 | $9.36 | $499.89K | 118,035 |
| Gregory Austin Ciongoli Director | Aug 26, 2026 | Buy | +49,196 | $9.14 | $449.65K | 64,628 |
| Gregory Austin Ciongoli Director | Aug 25, 2026 | Award | +15,432 | – | – | 15,432 |
| Steve Pakola Chief Medical Officer | Aug 1, 2026 | Tax withholding | −7,468 | $9.69 | $72.36K | 205,541 |
| Patrick J. Christmas Chief Strategy & Legal Officer | Aug 1, 2026 | Tax withholding | −4,699 | $9.69 | $45.53K | 205,968 |
| Steve Pakola Chief Medical Officer | Jul 2, 2026 | Option exercise | +2,161 | $7.86 | $16.99K | 215,170 |
| Steve Pakola Chief Medical Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −2,161 | $13.64 | $29.48K | 213,009 |
| Curran Simpson Chief Executive Officer, Director | Jul 1, 2026 | Tax withholding | −6,818 | $13.09 | $89.25K | 338,053 |
| Steve Pakola Chief Medical Officer | Jul 1, 2026 | Option exercise | +36,725 | $7.86 | $288.66K | 249,734 |
| Steve Pakola Chief Medical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −36,725 | $12.86 | $472.28K | 213,009 |
| Curran Simpson Chief Executive Officer, Director | Jun 30, 2026 | Award | +1,453 | $10.18 | $14.79K | 344,871 |
| Steve Pakola Chief Medical Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −19,608 | $11.04 | $216.47K | 213,009 |
| Alexandra Glucksmann Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| Allan M. Fox Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| Argeris N. Karabelas Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| Kenneth T. Mills Director | May 29, 2026 | Award | +9,807 | – | – | 495,925 |
| Jennifer Zachary Director | May 29, 2026 | Award | +9,807 | – | – | 31,871 |
| Daniel Tasse Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| David C. Stump Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| Jean Bennett Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| George V. Migausky Director | May 29, 2026 | Award | +9,807 | – | – | 28,861 |
| Steve Pakola Chief Medical Officer | May 11, 2026 | Sale(10b5-1 plan) | −15,309 | $11.02 | $168.71K | 232,617 |
| Steve Pakola Chief Medical Officer | Mar 10, 2026 | Sale(10b5-1 plan) | −5,124 | $10.35 | $53.03K | 247,926 |
| Steve Pakola Chief Medical Officer | Feb 1, 2026 | Tax withholding | −5,267 | $11.16 | $58.78K | 253,050 |
| Patrick J. Christmas Chief Strategy & Legal Officer | Feb 1, 2026 | Tax withholding | −4,700 | $11.16 | $52.45K | 210,667 |
| Kenneth T. Mills Director | Jan 27, 2026 | Option exercise | +225,000 | $13.09 | $2.95M | 707,871 |
| Kenneth T. Mills Director | Jan 27, 2026 | Tax withholding | −221,753 | $13.41 | $2.97M | 486,118 |
| Craig Malzahn Chief Technology Officer | Jan 6, 2026 | Award | +65,847 | – | – | 82,194 |
| Mitchell Chan Chief Financial Officer | Jan 6, 2026 | Award | +73,749 | – | – | 127,717 |
| Patrick J. Christmas Chief Strategy & Legal Officer | Jan 6, 2026 | Award | +73,749 | – | – | 215,367 |
| Curran Simpson Chief Executive Officer, Director | Jan 6, 2026 | Award | +144,864 | – | – | 342,467 |
| Steve Pakola Chief Medical Officer | Jan 6, 2026 | Award | +65,847 | – | – | 258,317 |
| Steve Pakola Chief Medical Officer | Jan 2, 2026 | Tax withholding | −18,247 | $14.40 | $262.76K | 192,470 |
| Craig Malzahn Chief Technology Officer | Jan 2, 2026 | Tax withholding | −1,238 | $14.40 | $17.83K | 16,347 |
| Patrick J. Christmas Chief Strategy & Legal Officer | Jan 2, 2026 | Tax withholding | −9,793 | $14.40 | $141.02K | 141,618 |
| Curran Simpson Chief Executive Officer, Director | Jan 2, 2026 | Tax withholding | −18,559 | $14.40 | $267.25K | 197,603 |
| Curran Simpson Chief Executive Officer, Director | Dec 31, 2025 | Award | +951 | $7.00 | $6.66K | 343,418 |
| Curran Simpson Chief Executive Officer, Director | Oct 9, 2025 | Sale(10b5-1 plan) | −20,811 | $12.62 | $262.63K | 216,162 |
| Curran Simpson Chief Executive Officer, Director | Sep 29, 2025 | Sale(10b5-1 plan) | −7,624 | $10.03 | $76.47K | 236,973 |
| Curran Simpson Chief Executive Officer, Director | Sep 10, 2025 | Sale(10b5-1 plan) | −7,734 | $10.02 | $77.49K | 244,597 |
| Craig Malzahn Chief Technology Officer | Sep 1, 2025 | Tax withholding | −234 | $8.93 | $2.09K | 17,585 |
| Mitchell Chan Chief Financial Officer | Sep 1, 2025 | Tax withholding | −4,901 | $8.93 | $43.77K | 53,968 |
| Patrick J. Christmas Chief Strategy & Legal Officer | Aug 1, 2025 | Tax withholding | −4,699 | $8.19 | $38.48K | 151,411 |
| Curran Simpson Chief Executive Officer, Director | Jul 1, 2025 | Tax withholding | −4,701 | $8.23 | $38.69K | 252,331 |
| Jennifer Zachary Director | May 30, 2025 | Award | +7,768 | – | – | 22,064 |
| George V. Migausky Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Kenneth T. Mills Director | May 30, 2025 | Award | +7,768 | – | – | 482,871 |
| Daniel Tasse Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Argeris N. Karabelas Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Allan M. Fox Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Jean Bennett Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Alexandra Glucksmann Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| David C. Stump Director | May 30, 2025 | Award | +7,768 | – | – | 19,054 |
| Kenneth T. Mills Director | May 12, 2025 | Sale(10b5-1 plan) | −20,602 | $7.91 | $162.96K | 475,103 |
| Kenneth T. Mills Director | May 12, 2025 | Option exercise | +20,602 | $3.76 | $77.46K | 495,705 |
| Kenneth T. Mills Director | Mar 27, 2025 | Option exercise | +30,752 | $3.76 | $115.63K | 475,103 |
| Patrick J. Christmas Chief Legal Officer | Feb 1, 2025 | Tax withholding | −4,700 | $8.07 | $37.93K | 156,110 |
| Olivier Danos Chief Scientific Officer | Feb 1, 2025 | Tax withholding | −5,452 | $8.07 | $44.00K | 226,348 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| J. Pakola Stephen Officer | Jul 1, 2026 | 43,206 | $517.61K | Jul 1, 2026 | Exercise of Stock Options |
| Pakola Stephen Officer | May 11, 2026 | 34,917 | $368.37K | May 11, 2026 | Restricted Stock Units |
| J. Pakola Stephen Officer | Mar 10, 2026 | 5,124 | $53.19K | Mar 10, 2026 | Restricted Stock Units |
| M. Simpson Curran Director, Officer | Oct 9, 2025 | 20,811 | $254.31K | Oct 9, 2025 | Restricted Stock Units |
| M. Simpson Curran Director, Officer | Sep 10, 2025 | 15,358 | $151.89K | Sep 10, 2025 | Restricted Stock Units |
| Mills Kenneth Director | May 12, 2025 | 20,602 | $154.93K | May 12, 2025 | Exercise of Stock Options |
| Vasista Vittal Officer | Dec 30, 2024 | 20,041 | $148.50K | Dec 30, 2024 | Previously Exercised Stock Options |
| N. Karabelas Argeris Director | Aug 1, 2024 | 31,000 | $441.75K | Aug 1, 2024 | Exercise of Stock Options |
| M. Simpson Curran Director, Officer | Jul 29, 2024 | 25,106 | $359.77K | Jul 29, 2024 | Restricted Stock Units |
| N. Karabelas Argeris Director | Jul 1, 2024 | 30,000 | $351.00K | Jul 1, 2024 | Exercise of Stock Options |
| Mills Kenneth Director, Officer | May 14, 2024 | 45,000 | $708.30K | May 14, 2024 | Exercise of Stock Options |
| J. Pakola Stephen Officer | Mar 5, 2024 | 12,878 | $275.07K | Mar 5, 2024 | Exercise of Stock Options |
| Thomas Mills Kenneth Director, Officer | Jan 16, 2024 | 90,000 | $1.36M | Jan 16, 2024 | Exercise of Stock Options |
| J. Pakola Stephen Officer | Jan 3, 2024 | 17,237 | $316.13K | Jan 3, 2024 | Restricted Stock Units |
| Thomas Mills Kenneth Director, Officer | Dec 19, 2023 | 45,000 | $877.95K | Dec 19, 2023 | Exercise of Stock Options |